Page 12 - Essa Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EPIX PHARMACEUTICALS (EPIX) - ESSA Pharma s Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study

EPIX PHARMACEUTICALS (EPIX) - ESSA Pharma s Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesEssa pharma incAmerican society of clinical oncology genitourinaryClinical oncologyஒன்றுபட்டது மாநிலங்களில்கட்டுரை பார்மா இன்க்மருத்துவ புற்றுநோயியல்

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020 News provided by Share this article Share this article VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ( ESSA , or the Company ) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2020. All references to $ in this release refer to United States dollars, unless otherwise indicated. ESSA s series of accomplishments over the past calendar year have included raising $48.9 million in an over-subscribed public offering, the granting by the U.S. Food and Drug Administration (the FDA ) of Fast Track Designation to our lead product candidate EPI-7386, and the initiation of a Phase 1 trial with EPI-7386 for patients with metastatic castration-resistant

United statesBritish columbiaDavid parkinsonServices disclosureDrug administrationJanssen research developmentExchange commissionHealth canadaPharma incVenture exchangeFast track designationJanssen researchRegistration statementUnited states securitiesCommon sharesOutstanding share

AnaptysBio (NASDAQ:ANAB), EPIX PHARMACEUTICALS (EPIX) - Why ESSA Pharma, AnaptysBio And More Are Moving Today

Share: ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced forms of prostate cancer at ASCO Genitourinary Cancers Symposium. ESSA Pharma engages in the development of small molecule drugs for prostate cancer. Realm is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies. ESSA Pharma stock was up 41.25% at $27.36. The stock has a 52-week high of $32.69 and a 52-week low of $3. Pacific Biosciences Of California (NASDAQ: PACB) shares are trading higher after the company reported better-than-expected 4 EPS and sales results.

United statesPacific biosciencesPiper sandlerVanda pharmaceuticals incEssa pharma incAnaptysbio incJp morganVanda pharmaceuticalsCalifornia incBiosciences of californiaBio incPharmaceuticals incஒன்றுபட்டது மாநிலங்களில்பெஸிஃபிக் உயிர் அறிவியல்பைபர் சாண்ட்லர்வந்தா மருந்துகள் இன்க்

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

Share this article VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ( ESSA , or the Company ) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today will present preclinical and clinical pharmacology data from ESSA s Phase 1 clinical trial of EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer ( mCRPC ) at the 2021 American Society of Clinical Oncology Genitourinary ( ASCO GU ) Cancers Symposium. EPI-7386, ESSA s lead product candidate, is an investigational, highly-selective, oral, small molecule inhibitor of the androgen receptor s N-terminal domain. ASCO GU is being held virtually from Thursday, February 11 to Saturday, February 13, 2021.

United statesBritish columbiaDavidr parkinsonHealth canadaPharma incClinical oncology genitourinaryChief executive officerFast trackPrivate securities litigation reform actEssa pharma incஒன்றுபட்டது மாநிலங்களில்பிரிட்டிஷ் கொலம்பியாஆரோக்கியம் கனடாபார்மா இன்க்தலைமை நிர்வாகி அதிகாரிவேகமாக டிராக்